Cardiff Oncology (NASDAQ:CRDF - Free Report) had its price objective raised by HC Wainwright from $17.00 to $18.00 in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.
Cardiff Oncology Stock Performance
Shares of NASDAQ CRDF traded up $0.09 during midday trading on Friday, reaching $2.75. 797,384 shares of the stock were exchanged, compared to its average volume of 1,120,582. The company has a 50 day simple moving average of $3.14 and a 200 day simple moving average of $3.47. The stock has a market capitalization of $182.95 million, a P/E ratio of -2.93 and a beta of 1.81. Cardiff Oncology has a twelve month low of $2.01 and a twelve month high of $5.64.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.09 million. On average, research analysts expect that Cardiff Oncology will post -0.99 earnings per share for the current year.
Institutional Trading of Cardiff Oncology
Several institutional investors have recently added to or reduced their stakes in the stock. Blair William & Co. IL increased its holdings in Cardiff Oncology by 521.0% in the 1st quarter. Blair William & Co. IL now owns 1,751,274 shares of the company's stock valued at $5,499,000 after purchasing an additional 1,469,249 shares during the last quarter. Orbimed Advisors LLC purchased a new position in Cardiff Oncology in the 4th quarter valued at approximately $6,677,000. Acorn Capital Advisors LLC purchased a new position in Cardiff Oncology in the 4th quarter valued at approximately $6,260,000. Adage Capital Partners GP L.L.C. purchased a new position in Cardiff Oncology in the 4th quarter valued at approximately $5,609,000. Finally, Geode Capital Management LLC boosted its position in Cardiff Oncology by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock valued at $4,266,000 after buying an additional 54,646 shares during the period. Institutional investors and hedge funds own 16.29% of the company's stock.
About Cardiff Oncology
(
Get Free Report)
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Read More
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
